Abstract: Modified oligonucleotides 3'-NHP(O)(O.sup.-)O-5' phosphoramidates were synthesized on a solid phase support. The phosphoramidate analogs were found to have significantly increased resistance toward phosphodiesterase digestion. Thermal dissociation experiments demonstrated that these compounds form more stable duplexes than phosphodiesters with complementary DNA and particularly RNA strands. Further, the phosphoramidate analogs can also form stable triplexes with double-stranded DNA target, where under similar conditions parent phosphodiester compounds failed to do so.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
May 20, 1997
Assignee:
Lynx Therapeutics, Inc.
Inventors:
Sergei M. Gryaznov, Ronald G. Schultz, Jer-Kang Chen
Abstract: Genetic material encoding p30 and B1 peptides of Toxoplasma gondii has been isolated and characterized. This genetic material allows the production of peptides for use in diagnosis or immunization or can itself be directly used in hybridization assays.
Type:
Grant
Filed:
January 14, 1994
Date of Patent:
May 13, 1997
Assignee:
The Board of Trustees of the Leeland Stanford Junior University
Inventors:
John C. Boothroyd, James L. Burg, Lloyd H. Kasper
Abstract: Lambdoid phage comprising a matrix of proteins encapsulating a genome encoding first and second polypeptides of an autogenously assembling receptor and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a lambdoid phage tail protein matrix anchor domain fused to at least one of the polypeptides.
Type:
Grant
Filed:
August 5, 1994
Date of Patent:
May 6, 1997
Assignee:
The Scripps Research Institute
Inventors:
Ichiro Maruyama, Hiroko Maruyama, Sydney Brenner
Abstract: A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.
Type:
Grant
Filed:
May 4, 1995
Date of Patent:
April 29, 1997
Assignee:
SyStemix, Inc.
Inventors:
Hideto Kaneshima, Reiko Namikawa, Joseph M. McCune
Abstract: Modifications in the sequence of Aequorea wild-type GFP provide products having markedly different excitation and emission spectra from corresponding products from wild-type GFP. In one class of modifications, the product derived from the modified GFP exhibits an alteration in the ratio of two main excitation peaks observed with the product derived from wild-type GFP. In another class, the product derived from the modified GFP fluoresces at a shorter wavelength than the corresponding product from wild-type GFP. In yet another class of modifications, the product derived from the modified GFP exhibits only a single excitation peak and enhanced emission relative to the product derived from wild-type GFP.
Type:
Grant
Filed:
November 10, 1994
Date of Patent:
April 29, 1997
Assignee:
The Regents of the University of California
Abstract: Disclosed are (1) a DNA sequence encoding a mutant L3T4 protein which, when expressed on the surface of a cell, is capable of facilitating infection of the cell by human immunodeficiency virus; the mutant protein includes at least one amino acid residue substitution or deletion in a segment corresponding to the gp120 binding epitope of a native L3T4 protein so as to increase homology between that segment and its counterpart in a CD4 protein; (2) a murine cell line or strain transfected with such a DNA sequence; and (3) a transgenic rodent susceptible to infection by human immunodeficiency virus.
Abstract: Mice lacking expression of CD28 or particular CD45 isoforms in certain cells of the immune system are provided. Also provided are methods of using these mice.
Type:
Grant
Filed:
September 14, 1995
Date of Patent:
April 1, 1997
Assignees:
Ontario Cancer Institute, Craig B. Thompson
Abstract: Disclosed are DNA sequences encoding DNA binding polypeptides including androgen receptor (AR) and TR2 polypeptides. Illustratively, human and rat AR-cDNA have 79 kD and 98 kD polypeptide expression products which are immunoprecipitable by human auto-immune anti-androgen receptor antibodies and are capable of binding androgens specifically and with high affinity. Also disclosed are antibodies and immunological methods and materials for detection of androgen receptor and TR2 polypeptides and hybridization methods and materials for detection of AR-and TR2-related nucleic acids.
Abstract: Functional analysis of genes is provided by employing insertional mutagenesis to a population of DNA molecules containing the gene of interest. The DNA is subjected to a degree of insertion, where the total population of molecules provides for a substantially complete representation of insertion across the length of DNA. The DNA is then subjected to a functional selection. The effect of the selection is determined by amplifying DNA isolated from selected and control populations, and determining whether a particular region is over or underrepresented in the amplified DNA.
Type:
Grant
Filed:
May 23, 1994
Date of Patent:
March 18, 1997
Assignee:
Board of Trustees of the Leland Stanford Junior University
Abstract: A process for producing recombinant human serum albumin is disclosed, which comprises culturing a human serum albumin-producing host, prepared by gene manipulation techniques in a medium that contains an amino acid, preferably at least one amino acid selected from the group consisting of alanine, aspartic acid, glutamic acid, histidine, serine, tryptophan, valine, isoleucine, phenylalanine, cysteine and arginine, more preferably histidine. The process can significantly increase the yield of human serum albumin over that produced by known processes.
Abstract: A method is provided for screening compounds for the ability to supress thymocyte depletion in thymuses of HIV-infected individuals, particularly enhancing the CD4.sup.+ -expressing population as compared to an untreated individual. Particularly, drugs are provided which allow for this result, cyclosporine A being exemplary.
Type:
Grant
Filed:
January 18, 1994
Date of Patent:
March 18, 1997
Assignee:
Systemix, Inc.
Inventors:
Mark L. Bonyhadi, Hideto Kaneshima, Joseph M. McCune, Reiko Namikawa, Lishan Su
Abstract: The present invention pertains to methods of monitoring mycoplasmal growth whereby a culture of mycoplasmal cells is contacted with a fluorescent nucleic acid-binding agent under conditions which allow the agent to selectively bind to mycoplasmal nucleic acid. The amount of fluorescence associated with the mycoplasmal nucleic acid indicates the number of mycoplasmal cells in the culture. The fluorescence of the culture is typically read using a fluorometer which correlates with colonial growth on agar. A particularly preferred fluorescent nucleic acid-binding agent is ethidium bromide. The present invention further pertains to methods of determining the effectiveness of an antimycoplasmal antibiotic.
Abstract: The invention provides a method of tracking, identifying, and/or sorting classes or subpopulations of molecules by the use of oligonucleotide tags. Oligonucleotide tags of the invention each consist of a plurality of subunits 3 to 6 nucleotides in length selected from a minimally cross-hybridizing set. A subunit of a minimally cross-hybridizing set forms a duplex or triplex having two or more mismatches with the complement of any other subunit of the same set. The number of oligonucleotide tags available in a particular embodiment depends on the number of subunits per tag and on the length of the subunit. An important aspect of the invention is the use of the oligonucleotide tags for sorting polynucleotides by specifically hybridizing tags attached to the polynucleotides to their complements on solid phase supports.
Abstract: A transgenic mouse which contains a predefined, specific and desired alteration in at least one of its two chromosomal alleles of a cellular adhesion gene, such that at least one of these alleles contains a mutation which alters the expression of the allele.
Type:
Grant
Filed:
September 20, 1994
Date of Patent:
February 11, 1997
Assignee:
Baylor College of Medicine
Inventors:
Arthur L. Beaudet, Raymond Wilson, Allan Bradley, William E. O'Brien, James Sligh, Christie Ballantyne, Daniel Bullard
Abstract: The present invention relates to the synthesis of functional human hemoglobin and other proteins in erythroid tissues of transgenic non-human animals and erythroid cell lines. It is based on the discovery that two of the five hypersensitivity sites of the .beta.-globin locus are sufficient to result in high level expression of human .alpha.- or .beta.-globin transgenes. The present invention also provides for novel recombinant nucleic acid vectors which may be used to produce .alpha.-globin as well as other proteins of interest in quantity in the red blood cells of transgenic animals or cell cultures of erythroid lineage. The vectors of the invention comprise at least one of the major DNase I hypersensitivity sites associated with the .beta.-globin locus together with a gene of interest. In a specific embodiment of the invention, a vector which comprises two DNase I hypersensitivity sites together with the human .alpha.-globin gene is used to create transgenic animals which produce human .alpha.
Type:
Grant
Filed:
July 13, 1994
Date of Patent:
February 11, 1997
Assignees:
The UAB Research Foundation, The Trustees of the University of Pennslyvania, Board of Regents of the University of Washington
Inventors:
Tim M. Townes, Thomas M. Ryan, Richard D. Palmiter, Ralph L. Brinster, Richard R. Behringer
Abstract: Non-tumorigenic cell lines capable of indefinite growth in serum-free media are disclosed. The cell lines are capable of expressing exogenously introduced genes, and may be derived from mouse embryo cells. Methods for producing proteins utilizing these cell lines, and methods for selectively controlling the growth of the cell lines are also disclosed.
Abstract: Expession of a target gene or transene in catecholaminergic cells of a transgenic mammal operably linked to the 5' flanlking sequence of a rat tyrosine hydroxylase gene is disclosed as well as immortalized catecholaminergic neuronal cell lines employing an oncogene operably linked to the 5' flanking sequence of a rat tyrosine hydroxylase gene.
Abstract: Transgenic mice having a phenotype characterized by the substantial depletion of a mature lymphocytic cell type otherwise naturally occurring in the species from which the transgenic mouse is derived. The phenotype is conferred in the transgenic mouse by a transgene contained in at least the precursor stem cell of the lymphocytic cell type which is depleted. The transgene comprised is a DNA sequence encoding a lymphatic polypeptide variant which inhibits maturation of the lymphocytic cell type.
Type:
Grant
Filed:
May 30, 1995
Date of Patent:
January 7, 1997
Assignee:
GenPharm International, Inc.
Inventors:
Paulus J. A. Krimpenfort, Antonius J. M. Berns
Abstract: An assay for monitoring and assessing the mutagenic potential of agents which involves creating transgenic non-human animals carrying a test DNA-sequence or sequences that can be quickly recovered and examined for mutations following exposure to one or more suspected mutagenic agents.